Introduction {#s0005}
============

Cancer progression to metastasis contributes to the poor prognosis of cancer patients due to the aggressive and invasive behavior of cancer cells that evade the immune system and establish tumors at distant organs. Therefore, there is a critical need to design and develop therapeutics that can block cancer cell invasion and migration away from the primary tumor [@bb0005], [@bb0010]. The closely related members of the Rho family, Rac and Cdc42, have been extensively studied due to their pivotal roles in actin cytoskeleton organization, migration/invasion and metastasis, epithelial to mesenchymal transition, transcription, cell proliferation, cell cycle progression, apoptosis, vesicle trafficking, angiogenesis, and cell adhesions [@bb0015], [@bb0020], [@bb0025]. Indeed, studies from us and others have implicated hyperactive Rac1 and Rac3 with increased survival, proliferation, and invasion of many cancer types [@bb0030], [@bb0035], [@bb0040], [@bb0045], [@bb0050]. In addition to promoting cancer malignancy, Rac and Cdc42 have also been shown to be essential for Ras and other oncogene-mediated transformation [@bb0055], [@bb0060].

Racs [@bb0005], [@bb0010], [@bb0015] are activated by a myriad of cell surface receptors that include: integrins, G protein coupled receptors, growth factor receptors, and cytokine receptors. These cell surface receptors regulate cancer promoting signal cascades that have been implicated with Rac and its direct downstream effector p21-activated kinase (PAK) activity [@bb0065]. These pathways include: phosphoinositide 3-kinase (PI3-K)/Akt/mammalian target of Rapamycin (mTOR); signal transducer and activator of transcription (STATs); and the mitogen activated protein kinases (MAPKs): extracellular regulated kinase (ERK), jun kinase (JNK), and p38 MAPK [@bb0070], [@bb0075], [@bb0080], [@bb0085], [@bb0090]. Activated Rac has also been shown to affect cell proliferation via signaling to the oncogenes c-Myc and Cyclin D [@bb0095]. Therefore, Rac GTPases play a pivotal role in regulation of cancer malignancy, and targeting Racs appear to be a viable strategy to impede cancer metastasis [@bb0040], [@bb0075], [@bb0100], [@bb0105].

Unlike Ras, Rho GTPases are not mutated in disease but activated via the deregulation of expression and/or activity of their upstream regulators, guanine nucleotide exchange factors (GEFs) [@bb0110]. Accordingly, although \~ 9% of melanomas were recently found to contain an activating Rac mutation [@bb0115], and the hyperactive splice variant Rac1b is frequently overexpressed in cancer [@bb0120], a majority of the Rac proteins in human cancer are activated due to up-regulated GEFs [@bb0105], [@bb0125], [@bb0130]. So far, over 70 potential Rac GEFs are known; and many members of the largest family of Rac GEFs, the Dbl family, have been identified as oncogenes [@bb0110], [@bb0135], [@bb0140], [@bb0145]. Of the Rac GEFs, T-cell invasion and metastasis gene product (Tiam-1), Trio, Vav (1/2/3), and PIP3-dependent Rac exchanger (p-Rex1/2) have been implicated in the progression of metastatic breast and other cancers [@bb0150], [@bb0155], [@bb0160], [@bb0165], [@bb0170], [@bb0175]. Therefore, the binding of GEFs to Rac and Cdc42 has been targeted as a rational strategy to inhibit their activity; and thus, metastasis.

The Rac inhibitor NSC23766 was identified as a small molecule compound that inhibits the interaction of Rac with the GEFs Trio and Tiam1 [@bb0180], [@bb0185], [@bb0190]. NSC23766 has been used to demonstrate the significance of Rac activity in cancer cell proliferation, survival, migration, metastasis, and therapy resistance [@bb0050], [@bb0195], [@bb0200], [@bb0205], [@bb0210], [@bb0215]. However, the high effective concentrations (IC~50~ \> 75 μM) of NSC23766 limit its use as a therapeutic agent [@bb0180]. Other known Rac inhibitors also have IC~50~s of 10 to 50 μM [@bb0220], [@bb0225]; including the recently published Rac inhibitors AZA1, ZINC69391, and IA-116 [@bb0230], [@bb0235]. At concentrations ranging from 5 to 20 μM, AZA1 acted as a dual inhibitor for Rac and Cdc42, and blocked prostate cancer cell proliferation, cell migration, and reduced Cyclin D1, and PAK and Akt activities [@bb0230]. Another compound ZINC69361, which inhibited Rac activity with an IC~50~ of 61 μM and reduced lung metastasis, was used as a lead to derive IA-116, which was selective for Rac and inhibited the interaction between Rac and the Rac GEF p-Rex1; albeit, at μM effective concentrations [@bb0235].

Recent studies have also shown the utility of the NSC23766 derivative AZA197, which was identified as a selective inhibitor for the closely related Rac homolog Cdc42. AZA197, at 1 to 10 μM, inhibited the Cdc42 GEF Dbs activity, PAK and ERK activities, and reduced Cyclin D levels, colon cancer cell proliferation, and cancer progression in a mouse model [@bb0240]. The potency of this inhibitor is similar to that of ML141 (CID2950007), another Cdc42 selective inhibitor with an IC~50~ \~ 3 to 5 μM [@bb0245], that was shown to inhibit melanoma cell migration [@bb0250]. These data demonstrate the utility of developing chemical probes to target both Rac and Cdc42 in malignant cancer.

To improve the efficacy of NSC23766 and its derivatives, we developed a panel of related compounds [@bb0255], and identified EHop-016 as a Rac inhibitor that is 100 times more potent than NSC23766, and binds to the effector domain of Rac1 with a tighter interaction [@bb0260]. To our knowledge, EHop-016 is one of the most potent Rac inhibitors that has been published, and is an effective tool for probing Rac function in cell and mouse models; as has been shown by us and others, in studies using breast cancer cell lines, leukemia, melanoma, and T lymphocytes [@bb0250], [@bb0260], [@bb0265], [@bb0270]. We reported that EHop-016 inhibits the Rac activity of metastatic cancer cells with an IC~50~ of 1 μM by blocking the specific interaction of Rac with the Rac GEF and oncogene Vav. EHop-016 also inhibits the activity of the Rac downstream effector PAK, lamellipodia extension, and cell migration in metastatic cancer cells at concentrations less than 10 μM, while concentrations ≥ 10 μM inhibits the activity of the close Rac homolog Cdc42, and cell viability [@bb0260], [@bb0265].

The aim of this study was to test the In Vivo effects of EHop-016 in cancer progression. We used metastatic cancer cell lines and a mouse model of experimental metastasis to demonstrate the efficacy of EHop-016 at reducing mammary fat pad tumor growth, metastasis, and angiogenesis. We also found that EHop-016 inhibited cell survival and proliferation regulators, and induced apoptosis in metastatic cancer cells; thus, highlighting its potential as an anticancer compound.

Materials and Methods {#s0010}
=====================

Cell Culture {#s0015}
------------

The human metastatic breast cancer cell line MDA-MB-435 expressing green fluorescent protein (GFP) (kind gift of Dr. Danny Welch, The University of Alabama at Birmingham, AL, 2009) was cultured, as described in [@bb0275]. The prostate cancer cell line PC3 was purchased from American Type Culture Collection (ATCC, Manassas, VA) and was cultured in Roswell Park Memorial Institute (RPMI) Medium supplemented with 10% heat inactivated fetal bovine serum (FBS) at 37°C in 5% CO~2~. Primary Human Umbilical Vein Endothelial Cells (HUVECs) were purchased from ATCC and were cultured at 37°C in 5% CO~2~ using the endothelial cell growth kit-BBE media (Vascular cell Basal media + added supplements) from ATCC, as per manufacturer instructions.

EHop-016 Synthesis {#s0020}
------------------

Ehop-016 was synthesized as previously described by us in [@bb0260]. Stock solutions were made in 10% dH~2~O and 90% DMSO.

Immunohistochemistry {#s0025}
--------------------

Tumor specimens were embedded in optimal cutting temperature (OCT) medium. Sections (5 μm) were fixed for two minutes each in acetone, chloroform:acetone, and acetone at − 20°C. Washed slides were incubated in blocking buffer (3% horse serum, 3% goat serum) and then with anti-CD31 (1:50 dilution; Abcam, Cambridge, MA) overnight in a humid chamber at 4°C, followed by incubation with Alexa Fluor 594 goat anti-rabbit (1:2000; Life Technologies, Carlsbad, CA) for 1 h at room temperature. After washing with 1 × PBS, sections were counterstained with 49-6-diamidino-2-phenylindole (DAPI) (1:5,000; Santa Cruz Biotechnology, Santa Cruz, CA) and mounted. Digital photographs were obtained using a Nikon Eclipse TS 100 Inverted microscope (Nikon, Melville, NY) with the NIS-Elements F 3.0 software and a Zeiss AxiocamMRc (Carl Zeiss, Gottingen, Germany).

Capillary Tube Formation Assay {#s0030}
------------------------------

Capillary tube formation was analyzed using 1:5 Matrigel matrix (Corning, Tewksbury, MA) in ice-cold buffer (10 mM of Tris Base 0.7% NaCl, pH 8), solidified by incubation at 37°C for \~ 1.5 h. A total of 40,000 HUVECs/well, pre-treated with vehicle (0.1% DMSO) or 8 μM of Ehop-016 for 24 h, were seeded into Matrigel pre-coated (200 μl/well) 48-well plates. Fresh vehicle or 8 μM of Ehop-016 was added to the corresponding treatments during the assay. Tube formation was monitored following a 3 h incubation at 37°C and 5% CO~2~.

Rac Activity Assay {#s0035}
------------------

HUVECs or PC3 cells were treated with vehicle or 8 μM Ehop-016. After 24 h, cells were lysed and total protein was quantified using the Precision Red protein assay kit (Cytoskeleton, Inc., Denver, CO). Active Rac was pulled down using beads coupled to GST--p21-activated kinase (PAK)-Cdc42/Rac interactive binding (CRIB) motif (GST-PAK-PBD beads from Cytoskeleton, Denver, CO) as described in [@bb0035], [@bb0030]. Proteins were Western blotted using an anti-Rac antibody (Cell Signaling Technology, Inc., Danvers, MA). Positive bands were imaged using ChemiDoc MP system (Bio-Rad, Hercules, CA) and quantified using Image J software. Rac activity was determined as the Rac-GTP bound to the PAK--CRIB domain as a function of total Rac.

Apoptosis Assay {#s0040}
---------------

Apoptosis was measured by relative caspase 3/7 activity, as described in [@bb0280], using a Caspase-Glo3/7 Luminescence Assay Kit as per manufacturer's instructions (Promega, Corp., Madison, WI, USA). Following treatment of MDA-MB-435 cells with vehicle or Ehop-016 at 5, 10, or 25 μM, 100 μl of Caspase-3/7 Glo reagent was added and incubated at room temperature for 60 minutes. Caspase-3/7 activities were determined by quantifying luminescence.

Western Blotting {#s0045}
----------------

MDA-MB-435 or PC3 cells were treated with vehicle, or 4 or 8 μM Ehop-016 for 24 h. Cells were immediately lysed as in [@bb0285] and total protein was quantified using the Precision Red protein assay kit (Cytoskeleton, Inc., Denver, CO). Equal total protein amounts were Western blotted using anti-Akt, anti-phospho Akt^Thr308^, anti-JNK, anti-phospho JNK^Thr183/Try185^, anti-c-Myc, or anti-Cyclin D (Cell Signaling Technology, Inc., Danvers, MA) antibodies. The integrated density of positive bands was quantified using Image J software.

Animals {#s0050}
-------

All animal studies were conducted under approved protocol \#A8180112 by the University of Puerto Rico Medical Sciences Campus Institutional Animal Care and Use Committee, in accordance with the principles and procedures outlined in the NIH Guideline for the Care and Use of Laboratory Animals.

Female athymic nu/nu mice, 4 to 5 weeks old (Charles River Laboratories, Inc., Wilmington, MA) were maintained under pathogen-free conditions in HEPA-filtered cages (5 mice per cage) under controlled light (12 h light and dark cycle), temperature (22 to 24°C), and humidity (25%). The animals received autoclaved rodent diet (Tek Global, Harlan Teklad, Madison, WI) with 24.5% protein, 4.3% fat and 3.7% fiber and water ad libitum.

Tumor Establishment {#s0055}
-------------------

GFP-MDA-MB-435 cells (\~ 0.5 × 10^6^) in Matrigel (BD Biosciences, San Jose, CA) were injected at the fourth right mammary fat pad under isofluorane inhalation (1% to 3% in oxygen using an inhalation chamber at 2 L/min) to produce orthotopic primary tumors as described in [@bb0285]. After tumor establishment (1 wk post-inoculation), the animals from the same litter with similar weight and tumor size were randomly divided into experimental treatment groups. The study was initiated with 10 mice/group. However, due to unforeseen mouse deaths (but not from EHop-016-mediated toxicity), the numbers on the last day were: Vehicle, N = 6; 10 mg/kg BW, N = 8; and 25 mg/kg BW, N = 4.

Administration of EHop-016 {#s0060}
--------------------------

Mice were treated with vehicle (12.5% ethanol (Sigma-Aldrich, St. Louis, MO), 12.5% Cremophor (Sigma-Aldrich, St. Louis, MO), and 75% 1 × PBS pH 7.4), or 10 or 25 mg/kg BW Ehop-016 by intraperitoneal (i.p.) injection in a 100 μl volume every other day, 3 times a week. Treatments continued until sacrifice at day 55.

Whole Body Fluorescence Image Analysis {#s0065}
--------------------------------------

Mammary tumor growth was quantified as changes in the integrated density of GFP fluorescence, using methods developed by Hoffman and co-workers [@bb0290]. Mice were imaged one week following breast cancer cell inoculation (on day 1 of treatment administration) and once a week thereafter. The FluorVivo small animal In Vivo imaging system (INDEC Systems, Inc., Santa Clara, CA) was used for whole body imaging of GFP fluorescence.

Tumor fluorescence intensities were analyzed using Image J software (National Institutes of Health, Bethesda, MD). The final images were acquired on day 55. Relative tumor growth was calculated as the integrated density of fluorescence of each tumor on each day of imaging relative to the integrated density of fluorescence of the same tumor on day 1 of treatment administration, as described in [@bb0275], [@bb0285].

Analysis of Metastases {#s0070}
----------------------

Following sacrifice, lungs, kidneys, livers, and spleens were excised and immediately stored in liquid N~2~. Stored organs were thawed and analyzed using an Olympus MV10 fluorescence macro zoom system microscope and images acquired with an Olympus DP71 digital camera, as described in [@bb0285]. Each organ was imaged on both sides. The fluorescent lesions (green component of RGB images) were quantified for integrated density of fluorescent pixels using Image J software.

Ehop-016 Detection by Ultra Performance Liquid Chromatography/Tandem Mass Spectrometry (UPLC-MS/MS) {#s0075}
---------------------------------------------------------------------------------------------------

Plasma Ehop-016 was quantified using an automated UPLC system coupled to a triple quadrupole tandem mass spectrometer (MS/MS) (Agilent Technologies, Santa Clara, CA). The data was collected and analyzed by the Agilent MassHunter software package (Version B.05.01). The UPLC separations were performed on a Poroshell 120 EC-C18 column (50 mm × 3.0 mm) with 2.7 μm particle size (Agilent, CA) under gradient conditions with a mobile phase of 1 mM ammonium fluoride aqueous solution (solution A) and 50% Acetonitrile/50% methanol/0.1% formic acid solution (solution B) at a flow rate of 0.5 ml/min at 40 °C. The initial mobile phase composition was 65% of solution A and 35% of solution B. The content of solution B was increased by a linear gradient to 98% from 2.5 minutes to 3.0 minutes. After 4.5 minutes, the content of solution B was decreased by a linear gradient to 35%. Finally, the column was equilibrated at the initial conditions for 1.5 minutes. The total run time for analysis was 6.5 minutes and the injection volume was 1 μl.

Statistical Analysis {#s0080}
--------------------

Data are expressed as the mean ± SEM. Statistical analyses were done using Microsoft Excel and GraphPad Prism. Differences between groups were considered to be statistically significant at *P* ≤ .05. Differences between means for vehicle were compared with means for 10 mg/kg BW EHop-016 or 25 mg/kg BW Ehop-016 using Student's *t* test. One-way ANOVAs were also performed for all 3 groups and the statistical significance determined by Kruskal--Wallis test and Dunn's multiple comparisons test.

Results and Discussion {#s0085}
======================

Metastasis, the migration of cancer cells away from the primary tumor to establish secondary tumors at distant sites, is a major cause of failure in cancer therapy and patient survival. Thus, there is an urgent need for strategies that specifically target migratory, and thus, metastatic cancer cells [@bb0010]. The Rho GTPases Rac and Cdc42 have been implicated in cancer progression via control of cancer cell proliferation, survival, migration/invasion, and metastasis [@bb0010], [@bb0295], [@bb0300], [@bb0305]. Therefore, we initiated the development of Rac and Cdc42 inhibitors as potential anti metastatic cancer therapeutics, using the established Rac inhibitor NSC23766 as a lead compound [@bb0255]. Recently, we disclosed the development of EHop-016, which inhibits Rac activity of metastatic cancer cells with an IC~50~ of 1 μM, and is the first compound reported to inhibit the activation of Rac by the oncogenic GEF Vav. EHop-016 inhibits the activity of the Rac downstream effector PAK, lamellipodia extension, and cell migration of metastatic cancer cells. At higher concentrations (≥ 10 μM) EHop-016 also inhibits Cdc42 activity and cell viability [@bb0260]. Herein, our objective was to test the feasibility of EHop-016 as a tool to inhibit metastatic cancer progression, using an athymic nude mouse model of experimental metastasis.

EHop-016 Reduces Mammary Tumor Growth {#s0090}
-------------------------------------

EHop-016 was administered by interperitoneal (i.p.) injection to nude mice with mammary tumors established from GFP-tagged MDA-MB-435 human metastatic cancer cells. Tumor growth was quantified as a measure of the fluorescence intensity of the primary mammary tumor of each mouse relative to day 1 from fluorescence images acquired once a week for 8 weeks. Administration of 25 mg/kg BW EHop-016 three times a week for 8 weeks resulted in a \~ 80% reduction in tumor growth compared to vehicle. As determined by Students t test, the decrease in tumor growth at 25 mg/kg BW EHop-016 was statistically significant when compared to vehicle or 10 mg/kg BW EHop-016 for the final four weeks of the study ([Figure 1](#f0005){ref-type="fig"}, *A* and *B*). On the final day of imaging, the comparison of tumor intensities between 0 and 10 mg/kg BW treatments with 25 mg/kg BW treatment was statistically significant when compared by the Kruskall--Wallis test. The Dunn's multiple comparison test demonstrated statistical significance between 10 mg/kg BW treatment and the 25 mg/kg BW treatment, but not between 0 and the 25 mg/kg BW treatment. On the other hand, administration of 10 mg/kg BW EHop-016 did not cause significant changes in tumor growth when compared to the vehicle control ([Figure 1](#f0005){ref-type="fig"}*B*), as determined by the Students t test, as well as one-way ANOVA, using Kruskal-Wallis and Dunn's multiple comparisons tests. These results demonstrate a concentration dependent effect of Ehop-016 on tumor growth.Figure 1Effect of EHop-016 on mammary fat pad tumor growth. Athymic nude mice were inoculated at the mammary fat pad with GFP-MDA-MB-435 cells. Average relative tumor growth from fluorescence *in situ* images up to 55 days following 0, 10, or 25 mg/kg body weight (BW) EHop-016 (three times a week) was determined. (A) Relative tumor growth as a function of days following EHop-016 administration. (B) Average Relative tumor intensity on day 55 (N = 6, 0 mg/kg BW; N = 8,10 mg/kg BW; N = 4, 25 mg/kg BW). Error bars = SEM, \* = p \< 0.05. (C) Average mouse weight as a function of days following EHop-016 administration.

[Figure 1](#f0005){ref-type="fig"}*C* demonstrates that at 25 mg/kg BW, EHop-016 did not cause significant weight changes in the nude mice. Moreover, these animals did not demonstrate any gross phenotypical changes in skin color and malleability, or behavior. Alanine transaminase activity from liver lysates also demonstrated no change from vehicle controls (data not shown). Therefore, EHop-016 does not appear to be toxic to the animals at the effective concentration.

EHop-016 Levels in Mouse Plasma {#s0095}
-------------------------------

To determine whether adequate EHop-016 levels were being delivered to the tumor tissue, we quantified the EHop-016 concentration in mouse plasma from blood collected at the end of the study. Mice were treated with EHop-016 three times a week for 55 days, with the final i.p. administration at 12 h prior to blood collection from cardiac puncture. A method was developed using UPLC-MS/MS to quantify EHop-016 from mouse plasma. EHop-016 was detected at \~ 17 ng/ml or 23 ng/ml (0.0395 or 0.0534 μM) in the mouse plasma, following 12 h administration of 4.65 mM EHop-016 (10 mg/kg BW EHop-016) or 11.61 mM EHop-016 (25 mg/kg BW EHop-016), respectively, in 100 μl in a 20 g mouse ([Table 1](#t0005){ref-type="table"}). This low recovery rate in plasma may be due to a faster clearing rate of EHop-016 from the blood via high tissue absorbance of this highly lipophilic molecule. Alternatively, EHop-016 may become metabolized or become unavailable for detection due to sequestration by carrier proteins in the blood. These mechanisms of drug elimination from the mouse plasma are currently being explored.Table 1EHop-016 levels in mouse plasma. EHop-016 was detected at ng/ml quantities from mouse plasma, using UPLC-MS/MS, following 10, or 25 mg/kg BW EHop-016 for 12 h. Data are expressed as the Mean ± SEMEHop-016 Administered (mg/kg BW)Ehop-016 in plasma (ng/ml)1017.1 ± 4.62523.3 ± 6.5

EHop-016 Inhibits Metastasis {#s0100}
----------------------------

The In Vivo study was terminated at 55 days, and the distant organs were excised and quantified for fluorescent metastatic foci. As shown in [Figure 2](#f0010){ref-type="fig"} and [Table 2](#t0010){ref-type="table"}, EHop-016 at 25 mg/kg BW dramatically reduced metastasis to lung, liver, spleen, and kidneys.Figure 2Effect of EHop-016 on metastasis. Mammary fat pad tumors were established in athymic nude mice using GFP-MDA-MB-435 cells. Mice were treated with 0, 10, or 25 mg/kg body weight (BW) EHop-016 (three times a week) (N = 5). Lungs, livers, kidneys, and spleens were removed at necropsy and imaged for fluorescent metastatic foci. (A) Representative organs under fluorescence microscopy for 25 mg/kg BW Ehop-016 treatment. (B) Average integrated intensity of fluorescent metastatic foci/organ. Error bars = SEM, \* = p \< 0.05.Table 2Average integrated density (1 × 10^3^) of metastatic fociOrganLungSpleenLiverKidneyTreatmentVeh61.4157.497.67.4Ehop-016 (25 mg/kg BW)0.7305.20

A number of studies have implicated Rac in cancer metastasis [@bb0075], [@bb0310]. Therefore, our results ([Figure 1](#f0005){ref-type="fig"}, [Figure 2](#f0010){ref-type="fig"} and [Table 2](#t0010){ref-type="table"}) further implicate Rac in the regulation of tumor growth and metastasis and demonstrate the utility of Rac inhibition as a strategy to block cancer progression. This study that demonstrates inhibition of metastasis, to all distant organs examined following EHop-016 treatment, may indicate that EHop-016 is inhibiting the intravasation step, when cancer cells migrate away from the primary mammary tumor to enter the circulation. Conversely, the marked reduction in tumor growth by EHop-016 may reduce the number of cells that are shed from the primary tumors and thus, effectively block metastasis. Future studies testing the effect of EHop-016 in spontaneous metastasis assays are expected to elucidate whether EHop-016 blocks the extravasation of metastatic cancer cells to establish metastases at distant sites.

EHop-016 Inhibits Angiogenesis {#s0105}
------------------------------

Angiogenesis is essential to cancer progression, where the endothelial cells in the tumor microenvironment form new blood vessels to sustain the growing tumor. A pertinent observation from our study was the relative lack of blood vessels at the surface of the mammary tumors from mice treated with 25 mg/kg BW EHop-016, compared to those treated with vehicle ([Figure 3](#f0015){ref-type="fig"}*A*). Therefore, tumor tissue was subjected to immunofluorescence for CD31, an endothelial cell marker. As expected, the tumors from mice that received vehicle controls demonstrated tubes arranged as capillaries. However, the tumors from mice that received EHop-016 demonstrated a \~ 85% decrease in capillary formation, as quantified from fluorescence micrographs (10 microscopic sections each for N = 2) of tissues stained for CD-31 for 0 and 25 mg/kg BW EHop-016 treatments ([Figure 3](#f0015){ref-type="fig"}*A*).Figure 3Effect of EHop-016 on angiogenesis. (A) Representative tumors from athymic nude mice inoculated at the mammary fat pad with GFP-MDA-MB-435 cells and treated with 0 or 25 mg/kg body weight (BW) EHop-016 (three times a week) (N = 5). Left, stereoscopic images of representative mammary tumors with blood vessels in red. Right, immunofluorescence micrographs of tissue sections with blood vessels stained for DAPI or CD31 (red fluorescence). (B) Representative micrographs following a tube formation assay using HUVEC cells treated with vehicle or 4 or 8 μM EHop-016 for 24 h (N = 4). Arrows indicate capillaries (tubes). (C) Representative Western blot and quantification of the Rac activity of HUVEC cells treated with 0 or 8 μM EHop-016 for 24 h from a pulldown assay for Rac.GTP (N = 2). Error bars = SEM, \* = P \< 0.05.

The ability of EHop-016 to inhibit Rac activity and capillary tube formation was also confirmed In Vitro using Human Umbilical Vein Endothelial Cells (HUVECs). As expected, EHop-016 inhibited the aggregation of endothelial cells into tubes. At 4 μM EHop-016, there was reduced tube formation, which was impaired at 8 μM, the concentration at which we observed a 50% reduction in Rac activity. ([Figure 3](#f0015){ref-type="fig"}*B*). Since Racs [@bb0005], [@bb0010] play an essential role in blood vessel morphogenesis via integrin signaling and endothelial cell proliferation/adhesion/migration mechanisms [@bb0315], [@bb0320], [@bb0325], we expect EHop-016 to additionally block tumor growth by reducing their blood supply via inhibition of the Rac activity of endothelial cells.

In this study, for the first time, we have shown that EHop-016 can be used effectively to block mammary tumor progression to metastasis. This anticancer activity of EHop-016 is predicted to be due to inhibition of Rac, and possibly Cdc42, activities in the human breast cancer cells as well as the endothelial cells in the tumor microenvironment. Therefore, EHop-016 may inhibit mammary tumor growth via multiple mechanisms of blocking the growth and migration of tumor cells and endothelial cells. Future studies will investigate the effect of EHop-016 on additional cells in the tumor microenvironment, such as macrophages and neutrophils as well as T and B lymphocytes that are regulated by Vav1/Rac2 signaling [@bb0330].

Recent studies have documented the utility of inhibiting Rac and Cdc42 to reduce tumor growth and metastasis in xenograft models. Another NSC23766 analog AZA1 (at 100 μg/day) was shown to inhibit Rac1 and Cdc42 in prostate cancer cells and reduce tumor growth via inhibition of Rac/Cdc42/PAK signaling to the actin cytoskeleton as well as Akt and Cyclin D to reduce cell survival and induce cell death [@bb0230]. The Rac GEF inhibitor ZINC639391 at 25 mg/kg BW, and its analog IA-116 at 3 mg/kg BW, resulted in reduced lung metastases from spontaneous metastases assays [@bb0235]. Similarly a Cdc42 specific inhibitor, AZA197, suppressed colon cancer growth via down-regulation of PAK and ERK activities, and Cyclin D1 expression [@bb0240]. Therefore, we expect EHop-016 to inhibit mammary tumor progression via multiple Rac/Cdc42/PAK-mediated signaling mechanisms.

EHop-016 Inhibits Rac/Cdc42/PAK-Mediated Cell Survival/Proliferation Signaling {#s0110}
------------------------------------------------------------------------------

To understand the mechanism by which EHop-016 reduces tumor growth, we investigated the effect of EHop-016 on apoptosis and cell survival signaling In Vitro. As previously shown by us, at concentrations ≥ 10 μM EHop-016 inhibits Rac and PAK activities by \~ 100% and Cdc42 activity by 75%, and reduces cell viability [@bb0260]. [Figure 4](#f0020){ref-type="fig"} shows that in MDA-MB-435 metastatic cancer cells, at concentrations ≥ 10 μM, EHop-016 increases caspase 3/7 activity in a statistically significant (*P* \< .05) and concentration-dependent manner with a maximum 1.6-fold induction at 25 μM, at concentrations that inhibit both Rac and Cdc42. This result indicates that EHop-016 may induce mitochondrial and death receptor-regulated apoptosis, and is consistent with a number of studies from various cancer types that have implicated a role for Rac/Cdc42/PAK signaling in cell survival and evasion of apoptosis [@bb0230], [@bb0265], [@bb0310].Figure 4Effect of EHop-016 on apoptosis and Rac/Cdc42/PAK signaling in MDA-MB-435 cells. A) Fold change in caspase 3/7 activity in response to EHop-016. MDA-MB-435 cells treated for 24 h with 0, 5, 10, or 25 μM EHop-016 and subjected to caspase 3/7 activity assays. N = 3 ± SEM, Asterisk = *P* \< .05. B-D. MDA-MB-435 cells treated with 0, 4, or 8 μM EHop-016 were lysed, and equal amounts of protein subjected to Western blotting followed by integrated density of positive bands. N = 2 to 5 ± SEM; Asterisk = *P* \< .05. (B) Representative Western blot stained for c-Myc or Cyclin D and quantification of relative protein expression. (C) Representative Western blot stained for phospho (p)-Akt, Akt, p-JNK, or JNK. (D) Quantification of relative protein phosphorylation.

Our previous studies demonstrated that EHop-016, at concentrations \< 10 μM, inhibits the Rac activity of metastatic breast cancer cells MDA-MB-435 and MDA-MB-231 [@bb0260], as well as the SKBR3 cell line (data not shown). To determine the potential of EHop-016 as a general Rac inhibitor, we also tested the effect of EHop-016 in the metastatic prostate cancer cell line PC3; a cell line that has been shown to be dependent on Rac/Vav signaling for migration/invasion [@bb0335]. [Figure 5](#f0025){ref-type="fig"}*A* demonstrates that 8 μM EHop-016 inhibits the Rac activity of PC3 cells by 50%.Figure 5Rac activity and expression of cell proliferation regulators in response to EHop-016 in PC3 cells. PC3 cells treated for 24 h with 8 μM EHop-016 were subjected to the following assays. (A) Rac activity determined by a pulldown assay for Rac.GTP. Representative Western blot showing positive bands for Rac.GTP and total Rac. Relative Rac activity was quantified from the positive bands from Western blots and represented as the ratio of active Rac/Total Rac. (B) JNK, c-Myc and cyclin D expression in response to 8 μM EHop-016. Representative Western blots and quantification of positive bands for relative protein expression is shown. N = 2--4 ± SEM, Asterisk = *P* \< .05.

To understand the mechanisms by which EHop-016 may reduce cell survival and induce apoptosis, we investigated the effect of EHop-016 on known Rac/Cdc42/PAK signaling pathway molecules, which have been implicated in controlling cell survival and proliferation. Activated Rac and Cdc42 may affect cell cycle progression via up-regulation of the oncogenes Cyclin D and c-Myc [@bb0050], [@bb0095], [@bb0340], [@bb0345], [@bb0350]. Rac/PAK signaling also regulates cell growth via signaling to Akt, ERK, JNK, and p38 MAPK [@bb0080], [@bb0355]. [Figure 4](#f0020){ref-type="fig"}, [Figure 5](#f0025){ref-type="fig"} show that in both MDA-MB-435 and PC3 cells, EHop-016 significantly reduced the expression of the oncogenic cell cycle regulators c-Myc and Cyclin D expression by \~ 25% to 60%.

Next, we investigated the effect of EHop-016 on MAPK activity and expression. EHop-016 did not affect ERK activity or expression (data not shown). However, EHop-016 significantly reduced the JNK activity of MDA-MB-435 cells by \~ 30%. In PC3 prostate cancer cells, p-JNK levels were decreased but total JNK levels were also reduced to a similar extent, indicating that JNK expression is also down-regulated in this cell line. Moreover, in the MDA-MB-435 cells, EHop-016 reduced Akt activity by 40% at 4 and 8 μM, without affecting the Akt activity of PC3 cells (data not shown). These differences may be attributed to disparate cancer types of the two different cell lines. Studies have also linked Akt activity and thus, the regulation of the anti-apoptotic protein BAD with Rac action [@bb0360], and may account of the observed reduction in caspase activity in the MDA-MB-435 cell line, where a parallel 1.4-fold calculated increase in caspase activity is observed at 8 μM, when Akt activity is decreased by − 1.4-fold ([Figure 4](#f0020){ref-type="fig"}, *A* and *B*). Therefore, EHop-016 may reduce cell viability and tumor growth via a number of Rac-regulated pathways that control cell survival and death.

Conclusions {#s0115}
===========

We have demonstrated that EHop-016 is a viable tool for blocking Rac activity via inhibition of the Vav/Rac interaction and thus, metastatic breast cancer cell migration In Vitro at μM concentrations [@bb0260]. Following this publication, the utility of EHop-016 as a Rac inhibitor has also been demonstrated in leukemia and melanoma cells [@bb0250], [@bb0265]. In this study, for the first time, we tested the efficacy of EHop-016 In Vivo. Our results, using a nude mouse model of experimental metastasis, demonstrate that EHop-016 significantly reduces mammary fat pad tumor growth and metastasis, as well as angiogenesis. The In Vitro assays with HUVEC cells, MDA-MB-435 cells, and PC3 cells further validate the use of EHop-016 to inhibit Rac, and thus, reduce cancer cell survival and proliferation, and inhibit metastatic cancer progression. Therefore, our data is significant for demonstrating the utility of developing chemical probes targeted at Rac, and the homolog Cdc42, as potential anti cancer therapeutics.
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